Delete search term


Quick navigation

Main navigation

Development of "next-generation" antibody drug conjugates for the treatment of lung cancer and multiple myeloma

At a glance

  • Project leader : Prof. Dr. Christiane Zaborosch
  • Deputy of project leader : Romina Dörig, Ramona Stark
  • Project team : Roland Josuran, Angelika Koller, Flavio Mehli
  • Project status : completed
  • Funding partner : Innosuisse
  • Contact person : Christiane Zaborosch


NBE-Therapeutics has developed novel "next-generation" homogeneous antibody drug conjugates (ADC) with proven efficacy in preclinical models of solid tumors, like lung and breast cancer, and hematological tumors, particularly in multiple myeloma. The goal of the project is to generate optimized ADC lead candidates from early candidates which will be guided by a rigorous assessment of the developability profiles of the ADC. It will include the development of advanced analytical assays and will lead to novel and optimized ADC candidates for clinical development.